Chinese Medical Industry Seeks Avenues To Globalize
This article was originally published in PharmAsia News
China's export of medical products has always exceeded its import, and trade surplus of the sector hit a new high last year. However, 2007 marked a turning point as the import growth rate overtook export increase for the first time by 1.5 percent. The president for the China Chamber of Commerce of Medicines and Health Products Importers and Exporters notes that rising internal competition and the impact of various health policies coming into effect mean globalization is the way to go. In the face of more challenges, domestic companies have to innovate and develop multiple markets. Some tap into foreign investors to list on overseas stock exchanges as an internationalization strategy. (Click here for more - Chinese Language)
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.